Regulatory clearances today put Zydus and Lilly in focus, while RPG Life Sciences restructures its API operations for greater efficiency.
This week’s GLP-1 battle intensifies as Novo slips, Roche climbs, and Lilly expands with major obesity and diabetes advances.
Regulatory Check Today shows the FDA backing two oral treatments while maintaining strict evidence standards for accelerated approval.
Sanofi reaffirms its India pharma bet with a 1,068 crore stake purchase, strengthening its local presence through an internal ownership shift.
AI drug discovery is gaining ground in India's pharmaceutical R&D landscape, with Rasayan Labs and ICT Mumbai bringing computational chemistry, molecular design and synthesis planning into a unified drug-discovery workflow.
Roche bets USD 2 billion on oral heart and metabolic pills through a discovery collaboration with Atavistik Bio targeting chronic diseases.
Diabetes care advances with new insulin, a new trial, and fresh funding, expanding treatment options for type 2 diabetes.
InnoCare and Eli Lilly have signed drug discovery pacts worth up to 3.35 billion, strengthening global interest in Chinese innovation.
Karnataka seeks wider medical device price controls as it flags unfair trade margins and rising healthcare costs for patients.
An FDA panel backed GRAIL's Galleri test, raising big questions for liquid biopsy and India's cancer care.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
